Schering-Plough says that its new fertility drug corifollitropin alfa has met its primary endpoints in a late-stage trial.

Data from the 1,509-patient non-inferiority ENGAGE trial for the sustained follicle stimulant were presented at the European Society of Human Reproduction and Embryology conference in Barcelona. They showed that the ongoing pregnancy rate, the primary endpoint of the trial, obtained in the 150 mcg corifollitropin alfa treatment arm (38.9% per started cycle) was similar to that achieved in patients receiving 200 IU recombinant FSH (follitropin beta), a standard hormone treatment.

S-P noted that the number of oocytes (female reproductive cells) retrieved, a co-primary endpoint, was “within the limits of clinical equivalence”. The company acquired the fertility treatments as part of its $14.4 billion acquisition of Organon Biosciences from Akzo Nobel.